Published research activities around the globe have identified many structures that are tumor specific or highly enriched on tumor cells. Using certain algorithms, those structures have been filtered and further investigated to provide a selection that are considered good candidates to be approached by systemic targeted radiotherapy.
Ariceum’s lead molecule, satoreotide, is a proprietary peptide derivative that binds to the somatostatin 2 receptor on certain tumor types. Satoreotide is an antagonist of the SSTR2 receptor. No biological activity is triggered in the tumor cells upon binding of satoreotide to the cell surface. The peptide’s only function is to (i) find and bind to SSTR2 on tumor cells and (ii) to deliver radioactivity to those tumor cells. Upon decay of the radioactive molecule, the alpha or beta particle emitted will severely damage and ultimately kill the tumor cell.
Other compounds in Ariceum’s pipeline will target different structures, and the targeting molecule may be anything from a small molecule to a large antibody.
The choice of targeting molecule will depend on the structure to be targeted and on the specific cancer indication (i.e. hematological or solid tumor).
Choice of Radioisotope
The choice of radioisotope will depend on the intended purpose. Isotopes ideal for imaging will be different from isotopes for optimal tumor eradication. In addition, the half-life of the isotopes and whether they emit alpha or beta particles will have an impact on their therapeutic utility.